Sangamo Therapeutics (SGMOQ) Non-Current Assets (2010 - 2025)

Sangamo Therapeutics has reported Non-Current Assets for 16 years, with the latest figure at $23.9 million in Q4 2025.

• On a quarterly basis, Non-Current Assets fell 52.12% year-over-year to $23.9 million in Q4 2025; TTM through Dec 2025 was $164.7 million, a 23.86% decrease from a year earlier, with the FY2025 full-year figure at $23.9 million, down 52.12% from the prior year.
• Non-Current Assets was $23.9 million for Q4 2025 at Sangamo Therapeutics, down from $44.6 million in the prior quarter.
• The five-year high for Non-Current Assets was $325.0 million in Q3 2021, with the low at $23.9 million in Q4 2025.
• Average Non-Current Assets over 5 years is $160.5 million, with a median of $118.8 million recorded in 2023.
• The sharpest annual moves came in 2021 and 2023: Non-Current Assets jumped 30.68% in 2021, then plunged 72.92% in 2023.
• Over 5 years, Non-Current Assets stood at $323.2 million in 2021, then fell by 18.87% to $262.2 million in 2022, then slumped by 72.92% to $71.0 million in 2023, then retreated by 29.65% to $49.9 million in 2024, then plunged by 52.12% to $23.9 million in 2025.
• The last three Non-Current Assets figures came in at $23.9 million (Q4 2025), $44.6 million (Q3 2025), and $47.7 million (Q2 2025), per Business Quant data.